1-5 of 5
Louis F. Stancato
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

Jian Du, Lei Yan, Raquel Torres, Xueqian Gong, Huimin Bian, Carlos Marugán, Karsten Boehnke, Carmen Baquero, Yu-Hua Hui, Sonya C. Chapman, Yanzhu Yang, Yi Zeng, Sarah M. Bogner, Robert T. Foreman, Andrew Capen, Gregory P. Donoho, Robert D. Van Horn, Darlene S. Barnard, Jack A. Dempsey, Richard P. Beckmann, Mark S. Marshall, Li-Chun Chio, Yuewei Qian, Yue W. Webster, Amit Aggarwal, Shaoyou Chu, Shobha Bhattachar, Louis F. Stancato, Michele S. Dowless, Phillip W. Iversen, Jason R. Manro, Jennie L. Walgren, Bartley W. Halstead, Matthew Z. Dieter, Ricardo Martinez, Shripad V. Bhagwat, Emiko L. Kreklau, Maria Jose Lallena, Xiang S. Ye, Bharvin K.R. Patel, Christoph Reinhard, Gregory D. Plowman, David A. Barda, James R. Henry, Sean G. Buchanan, Robert M. Campbell
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12): 2207–2219.
https://doi.org/10.1158/1535-7163.MCT-18-0529
Published: 02 December 2019
View article titled, Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy
Open the PDF for Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy in another window
Includes: Supplementary data
Journal Articles

Abstract LB-B01: The anti-platelet-derived growth factor receptor α antibody olaratumab (Lartruvo) increases overall survival in metastatic mouse models of human osteosarcoma

Amy K. LeBlanc, Gerard J. Oakley, Caitlin D. Lowery, Arnulfo Mendoza, Ling Ren, Timothy Holzer, Kelly Credille, Cynthia Winings, Amanda Estelle, Mia Chen, Patrick Finnegan, Wayne Blosser, Andrew Schade, Symantha Melemed, Louis F. Stancato
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-B01.
https://doi.org/10.1158/1535-7163.TARG-17-LB-B01
Published: 01 January 2018
View article titled, Abstract LB-B01: The anti-platelet-derived growth factor receptor α antibody olaratumab (Lartruvo) increases overall survival in metastatic mouse models of human osteosarcoma
Journal Articles

Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity

Robert M. Campbell, Bryan D. Anderson, Nathan A. Brooks, Harold B. Brooks, Edward M. Chan, Alfonso De Dios, Raymond Gilmour, Jeremy R. Graff, Enrique Jambrina, Mary Mader, Denis McCann, Songqing Na, Stephen H. Parsons, Susan E. Pratt, Chuan Shih, Louis F. Stancato, James J. Starling, Courtney Tate, Juan A. Velasco, Yong Wang, Xiang S. Ye
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (2): 364–374.
https://doi.org/10.1158/1535-7163.MCT-13-0513
Published: 09 February 2014
View article titled, Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Open the PDF for Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity in another window
Includes: Supplementary data
Journal Articles

Abstract B235: Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity.

Robert M. Campbell, Bryan D. Anderson, Edward M. Chan, Alfonso De Dios, Raymond Gilmour, Steven D. Hatch, Enrique Jambrina, Paul Lee, Mary Mader, Songqing Na, Blake L. Neubauer, Susan Pratt, Chuan Shih, Louis F. Stancato, James J. Starling, Juan A. Velasco, Scott A. Watkins, Jeffrey A. Wolos, Xiang Ye
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B235.
https://doi.org/10.1158/1535-7163.TARG-11-B235
Published: 12 November 2011
View article titled, Abstract B235: Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity.
Journal Articles

A Robust High-Content Imaging Approach for Probing the Mechanism of Action and Phenotypic Outcomes of Cell-Cycle Modulators

Jeffrey J. Sutherland, Jonathan Low, Wayne Blosser, Michele Dowless, Thomas A. Engler, Louis F. Stancato
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (2): 242–254.
https://doi.org/10.1158/1535-7163.MCT-10-0720
Published: 08 February 2011
View article titled, A Robust High-Content Imaging Approach for Probing the Mechanism of Action and Phenotypic Outcomes of Cell-Cycle Modulators
Open the PDF for A Robust High-Content Imaging Approach for Probing the Mechanism of Action and Phenotypic Outcomes of Cell-Cycle Modulators in another window
Includes: Supplementary data